TY - JOUR
T1 - Small molecule inhibitors and biologics in treating nail psoriasis
T2 - A systematic review and network meta-analysis
AU - Huang, I. Hsin
AU - Wu, Po Chien
AU - Yang, Ting Hua
AU - Li, Hua
AU - Huang, Yu Ting
AU - Cheng, Ying Chih
AU - Kuo, Po Hsiu
AU - Lee, Ya Han
AU - Huang, Yu Chen
AU - Tu, Yu Kang
N1 - Publisher Copyright:
© 2021 American Academy of Dermatology, Inc.
PY - 2021
Y1 - 2021
N2 - Background: Various systemic immunomodulating therapies have been investigated to treat nail psoriasis, but the efficacy remains unclear. Objective: To perform a systematic review and network meta-analysis to evaluate the efficacy of small molecule inhibitors and biologics in treating nail psoriasis. Methods: Eligible studies in online databases were identified until March 10, 2020. To assess the efficacy of small molecule inhibitors and biologics, network meta-analyses with surface under the cumulative ranking curve of improvement in nail score at 10 to 16 and at 24 to 26 weeks, as well as 100% improvement of Nail Psoriasis Severity Index (NAPSI), were performed. Results: Thirty-nine studies with a total of 13 treatment arms involving 15,673 patients with nail psoriasis were included. An network meta-analysis showed that tofacitinib (weighted mean difference, 56.67; 95% confidence interval [CI], 35.87-77.48) and ixekizumab (weighted mean difference, 59.40; 95% CI, 45.87-72.93) presented the most improvement of nail score at 10 to 16 weeks and 24 to 26 weeks, respectively. For 100% improvement of the Nail Psoriasis Severity Index, ixekizumab showed the best efficacy among all treatments (odds ratio, 2.98; 95% CI, 1.74-5.10). Limitations: Insufficiency of eligible data and no long-term follow-up data. Conclusion: Tofacitinib and ixekizumab presented the best efficacy for treating nail psoriasis in 10 to 16 weeks and 24 to 26 weeks, respectively.
AB - Background: Various systemic immunomodulating therapies have been investigated to treat nail psoriasis, but the efficacy remains unclear. Objective: To perform a systematic review and network meta-analysis to evaluate the efficacy of small molecule inhibitors and biologics in treating nail psoriasis. Methods: Eligible studies in online databases were identified until March 10, 2020. To assess the efficacy of small molecule inhibitors and biologics, network meta-analyses with surface under the cumulative ranking curve of improvement in nail score at 10 to 16 and at 24 to 26 weeks, as well as 100% improvement of Nail Psoriasis Severity Index (NAPSI), were performed. Results: Thirty-nine studies with a total of 13 treatment arms involving 15,673 patients with nail psoriasis were included. An network meta-analysis showed that tofacitinib (weighted mean difference, 56.67; 95% confidence interval [CI], 35.87-77.48) and ixekizumab (weighted mean difference, 59.40; 95% CI, 45.87-72.93) presented the most improvement of nail score at 10 to 16 weeks and 24 to 26 weeks, respectively. For 100% improvement of the Nail Psoriasis Severity Index, ixekizumab showed the best efficacy among all treatments (odds ratio, 2.98; 95% CI, 1.74-5.10). Limitations: Insufficiency of eligible data and no long-term follow-up data. Conclusion: Tofacitinib and ixekizumab presented the best efficacy for treating nail psoriasis in 10 to 16 weeks and 24 to 26 weeks, respectively.
KW - biologics
KW - nail psoriasis
KW - Nail Psoriasis Severity Index
KW - network meta-analysis
KW - small molecule inhibitors
UR - http://www.scopus.com/inward/record.url?scp=85103083320&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103083320&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2021.01.024
DO - 10.1016/j.jaad.2021.01.024
M3 - Article
C2 - 33482253
AN - SCOPUS:85103083320
SN - 0190-9622
VL - 85
SP - 135
EP - 143
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 1
ER -